Education
About Us
Working with TipRanks
Follow Us
Adynxx, Inc. (ADYX)
OTHER OTC:ADYX
ADYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume44.00
Average Volume (3M)0.00
Market Cap
$6.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-7.00
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
May 06, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,808,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ADYX FAQ
What was Adynxx, Inc.’s price range in the past 12 months?
Adynxx, Inc. lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Adynxx, Inc.’s market cap?
Adynxx, Inc.’s market cap is $6.00.
When is Adynxx, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Adynxx, Inc.’s earnings last quarter?
Currently, no data Available
Is Adynxx, Inc. overvalued?
According to Wall Street analysts Adynxx, Inc.’s price is currently Overvalued.
Does Adynxx, Inc. pay dividends?
Adynxx, Inc. pays a Monthly dividend of $6.3 which represents an annual dividend yield of N/A. See more information on Adynxx, Inc. dividends here
What is Adynxx, Inc.’s EPS estimate?
Adynxx, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adynxx, Inc. have?
Adynxx, Inc. has 5,808,000 shares outstanding.
What happened to Adynxx, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adynxx, Inc.?
Currently, no hedge funds are holding shares in ADYX
Company Description
Adynxx, Inc.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Adynxx (ADYX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
Evaxion Biotech
―
GRI Bio
―